News - GW Pharmaceuticals

Filter

Current filters:

GW Pharmaceuticals

Popular Filters

US orphan status for GW Pharma’s Epidiolex in Lennox-Gastaut syndrome

28-02-2014

UK-based GW Pharmaceuticals says that the Food and Drug Administration has granted orphan drug designation…

epidiolexGW PharmaceuticalsNeurologicalNorth AmericaPharmaceuticalRegulationUSA

GW Pharma revenues rise but 1st-qtr loss incurred

GW Pharma revenues rise but 1st-qtr loss incurred

05-02-2014

Shares of UK-based cannabis-based drug developer GW Pharmaceuticals fell 3,9% to 287.39 pence this morning,…

epidiolexFinancialGW PharmaceuticalsNeurologicalPharmaceuticalResearchSativex

Ipsen and GW Pharma to promote Sativex in Latin America; Ipsen will ‘go it alone’ for Somatuline

Ipsen and GW Pharma to promote Sativex in Latin America; Ipsen will ‘go it alone’ for Somatuline

14-01-2014

French drugmaker Ipsen (Euronext: IPN) and UK-based GW Pharmaceuticals (Nasdaq: GWPH) have entered into…

FranceGW PharmaceuticalsIpsenLicensingPharmaceuticalSativexSomatuline

Sativex approved for MS in Switzerland

Sativex approved for MS in Switzerland

27-11-2013

UK-based GW Pharmaceuticals (AIM: GWP), which is focused on novel cannaboid therapeutics, has received…

AlmirallCNS DiseasesEuropeGW PharmaceuticalsPharmaceuticalRegulationSativex

GW Pharma sees fiscal 2012/3 revenues decline, impacted by Sativex

GW Pharma sees fiscal 2012/3 revenues decline, impacted by Sativex

19-11-2013

UK-based GW Pharmaceuticals (AIM: GWP) which is focused on novel cannaboid therapeutics, has announced…

CNS DiseasesFinancialGW PharmaceuticalsPharmaceuticalSativexUK

GW Pharma receives FDA orphan drug designation for cannaboid-based agent

GW Pharma receives FDA orphan drug designation for cannaboid-based agent

15-11-2013

GW Pharmaceuticals (Nasdaq: GWPH) has been granted orphan drug designation by the US Food and Drug Administration…

EuropeGW PharmaceuticalsNorth AmericaPharmaceuticalRare diseasesRegulationUKUSA

Agreement reached for Sativex pricing in Germany

25-09-2013

A German unit of Spain’s largest drugmaker Almirall, Hermal GmbH and Germany’s National Association…

AlmirallEuropeGW PharmaceuticalsNeurologicalPharmaceuticalPricingSativex

GW Pharma goes into 3rd-qtr loss

05-08-2013

UK-based GW Pharmaceuticals (Nasdaq: GWPH, AIM: GWP) which is focused on discovering, developing and…

FinancialGW PharmaceuticalsPharmaceuticalSativex

GW Pharma posts six-month results; progresses cannabinoid pipeline including into diabetes and UC

05-06-2013

UK biopharma company GW Pharmaceuticals (AIM: GWP), which is developing and commercializing novel therapeutics…

DiabetesFinancialGastro-intestinalsGW PharmaceuticalsNeurologicalPharmaceuticalResearchSativex

Almirall pays GW Pharma milestone on Sativex; reports 1st-qtr results

07-05-2013

UK-based GW Pharmaceuticals (AIM: GWP) says that it has received commercialization approval for its cannabinoid-based…

AlmirallEuropeFinancialGW PharmaceuticalsNeurologicalPharmaceuticalRegulationSativex

Bayer's PAH drug candidate riociguat gets US priority review; Sativex rescheduled in UK

08-04-2013

The US Food and Drug Administration has granted priority review to German drug major Bayer's (BAYN: DE)…

BayerEuropeGW PharmaceuticalsNeurologicalNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryriociguatSativex

Almirall could pull Sativex from German market due to inadequate pricing

20-03-2013

Almirall (ALM: MC), Spain's largest pharma company and the licensee for UK-based GW Pharmaceuticals'…

AlmirallEuropeGW PharmaceuticalsNeurologicalPharmaceuticalPricingSativex

Highlights from ECTRIMS include new data for Gilenya, Sativex and Aubagio

14-10-2012

New data presented at the 28th congress of the European Committee for Treatment and Research in Multiple…

AlmirallAubagioBiotechnologyGenzymeGilenyaGW PharmaceuticalsNeurologicalNovartisPharmaceuticalResearchSanofiSativex

Spanish reforms and generics hit Almirall's 1st-qtr; Sativex progress

09-05-2012

Spain's leading drugmaker Almirall (ALM: MC) has reported a 5.9% decrease in sales for the first quarter…

AlmirallEuropeFinancialGW PharmaceuticalsNeurologicalPharmaceuticalRegulationSativex

No proof of added benefit of Sativex, says German IQWiG

17-04-2012

In an early benefit assessment under to the German Act on the Reform of the Market for Medicinal Products…

AlmirallEuropeGW PharmaceuticalsNeurologicalPharmaceuticalPricingRegulationSativex

GW Pharma and Almirall extend Sativex deal to Mexico

15-03-2012

UK-based GW Pharmaceuticals (AIM: GWP) announces that it has signed an amendment to its cannabis-based…

AlmirallFinancialGW PharmaceuticalsLicensingNeurologicalPharmaceuticalSativexSouth America

GW Pharma’s Sativex cleared in Austria

07-02-2012

The UK’s GW Pharmaceuticals’ (AIM: GWP) Sativex (delta-9-tetrahydrocannabinol (THC) and cannabidiol…

AlmirallEuropeGW PharmaceuticalsNeurologicalPharmaceuticalRegulationSativex

Spain’s Almirall launches Sativex and gets OK for Actikerall in Germany

06-07-2011

Spain’s largest pharmaceutical firm, Almirall (ALM: MC) yesterday announced the German launch of…

ActikerallAlmirallDermatologicalsEuropeGW PharmaceuticalsMarkets & MarketingNeurologicalOncologyPharmaceuticalRegulationSativex

German approval for GW and Almirall’s Sativex for spasticity due to MS

27-05-2011

Spain’s leading drugmaker Almirall (ALM) and UK-based originator of the cannabis based product GW…

AlmirallEuropeGW PharmaceuticalsNeurologicalPharmaceuticalRegulationSativex

Back to top